Trima Non-DEHP Leukoreduced Red Blood C… | Clinical Trial

Key information

Conditions

Device Validation of In-vivo Performance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hoxworth Blood Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Given written informed consent.
Age 18 years or older.
Normal health status as per AABB criteria for healthy donor.
Able to commit to the study schedule.
Meets the inclusion criteria defined by site SOPs for automated blood component collection systems or whole blood donation. These criteria are based on AABB standards and FDA regulations.

a. Note: Participants who are deferred from volunteer community donations due to certain restrictions may participate in the study, as products are not used for allogeneic transfusion; however, sites may or may not implement this depending on their standard procedures.

Participants of childbearing potential (either male or female) must agree to use a medically acceptable method of contraception throughout the study.
Female participants of childbearing potential must agree to take a pregnancy test prior to the apheresis procedure and prior to reinfusion of radiolabeled LR-RBCs.
Participants must agree to report AEs throughout their participation in the study

Exclusion criteria

Currently pregnant or nursing females.
Serum ferritin less than12 ng/mL
Has previously completed this study with data included in the EAS.
Participation currently, or within the past 30 days, in another investigational trial that would potentially interfere with the analysis of this investigation (eg, pharmaceutical trial).
As determined by the Investigator:

Has been diagnosed with a blood disorder(s) affecting RBC characteristics (eg, Glucose 6 Phosphate Dehydrogenase Deficiency [G6PD]),
Reported history of RBC autoantibodies/autoimmune hemolytic anemia, RBC alloantibodies,
Clinically significant acute or chronic disease, or
Reported history of hypersensitivity to technetium or chromium
Other unspecified reason that, in the opinion of the Investigator, makes the healthy adult volunteer unsuitable for enrollment.
Treatment with any medication as specified in site deferral list (based on AABB medication deferral list for apheresis donors).
Previously transfused/reinfused with RBCs within the last 120 days.

Treatment and study plan

Trima Accel Auto RBC Collection

Device

This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from Trima Accel Auto RBC collection.

Primary outcomes

Number of Participants With Success of RBCs in Vivo Recovery After 42-day Storage (Single-label Method)

Time frame: 43 days
The primary outcome of this study is to demonstrate that LR-RBCs collected on the Trima Accel system using non-DEHP disposable tubing sets with AS-3 meet the FDA criteria for 24-hour recovery after 42 days of refrigerated storage in non-DEHP storage bags.

The 3 parts of FDA RBC recovery criteria that must be met (below) are presented in Primary Outcome 1 and Primary Outcome 2. The derivation of the sample size was based on the level of precision attained with 26 subjects relative to the 1st part of the criteria.
- A one-sided lower confidence limit for the proportion of RBC components with 24-hour RBC in vivo recovery less than 75% is 70%* (Primary Outcome 1),
*Allows for low recoveries (< 75%) in up to 3 out of 24 to 26 participants
- A sample mean of in vivo 24-hour RBC percent recovery ≥ 75% (Primary Outcome 2)
- A sample standard deviation of in vivo 24-hour percent RBC recovery ≤ 9% (Primary Outcome 2)
Number of Participants With Success of RBCs in Vivo Recovery After 42-day Storage (Dual-label Method)

Time frame: 43 days
The primary outcome of this study is to demonstrate that LR-RBCs collected on the Trima Accel system using non-DEHP disposable tubing sets with AS-3 meet the FDA criteria for 24-hour recovery after 42 days of refrigerated storage in non-DEHP storage bags.

The 3 parts of FDA RBC recovery criteria that must be met (below) are presented in Primary Outcome 1 and Primary Outcome 2. The derivation of the sample size was based on the level of precision attained with 26 subjects relative to the 1st part of the criteria.
- A one-sided lower confidence limit for the proportion of RBC components with 24-hour RBC in vivo recovery less than 75% is 70%* (Primary Outcome 1),
*Allows for low recoveries (< 75%) in up to 3 out of 24 to 26 participants
- A sample mean of in vivo 24-hour RBC percent recovery ≥ 75% (Primary Outcome 2)
- A sample standard deviation of in vivo 24-hour percent RBC recovery ≤ 9% (Primary Outcome 2)
Mean 24-hour, Post-transfusion, in Vivo RBC Recovery Percentage After 42-day Storage (Single-label Method)

Time frame: 43 days
The primary outcome of this study is to demonstrate that LR-RBCs collected on the Trima Accel system using non-DEHP disposable tubing sets with AS-3 meet the FDA criteria for 24-hour recovery after 42 days of refrigerated storage in non-DEHP storage bags.

The 3 parts of FDA RBC recovery criteria that must be met (below) are presented in Primary Outcome 1 and Primary Outcome 2. The derivation of the sample size was based on the level of precision attained with 26 subjects relative to the 1st part of the criteria.
- A one-sided lower confidence limit for the proportion of RBC components with 24-hour RBC in vivo recovery less than 75% is 70%* (Primary Outcome 1),
*Allows for low recoveries (< 75%) in up to 3 out of 24 to 26 participants
- A sample mean of in vivo 24-hour RBC percent recovery ≥ 75% (Primary Outcome 2)
- A sample standard deviation of in vivo 24-hour percent RBC recovery ≤ 9% (Primary Outcome 2)
Mean 24-hour, Post-transfusion, in Vivo RBC Recovery Percentage After 42-day Storage (Dual-label Method)

Time frame: 43 days
The primary outcome of this study is to demonstrate that LR-RBCs collected on the Trima Accel system using non-DEHP disposable tubing sets with AS-3 meet the FDA criteria for 24-hour recovery after 42 days of refrigerated storage in non-DEHP storage bags.

The 3 parts of FDA RBC recovery criteria that must be met (below) are presented in Primary Outcome 1 and Primary Outcome 2. The derivation of the sample size was based on the level of precision attained with 26 subjects relative to the 1st part of the criteria.
- A one-sided lower confidence limit for the proportion of RBC components with 24-hour RBC in vivo recovery less than 75% is 70%* (Primary Outcome 1),
*Allows for low recoveries (< 75%) in up to 3 out of 24 to 26 participants
- A sample mean of in vivo 24-hour RBC percent recovery ≥ 75% (Primary Outcome 2)
- A sample standard deviation of in vivo 24-hour percent RBC recovery ≤ 9% (Primary Outcome 2)

Sponsors and collaborators

Lead sponsor

Terumo BCT

Industry

Registry information

Official study title

In Vivo 24-Hour Recovery Study of Leukoreduced RBCs Collected on the Trima Accel System Using Non-DEHP Disposable Sets and Stored for 42 Days

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Sep 19, 2024
Registry last updated: Feb 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed

An In Vivo 24-Hour Recovery Study of Whole Blood by the Reveos System

NCT05239455